NanoVibronix Inc
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increa… Read more
NanoVibronix Inc (NAOV) - Total Assets
Latest total assets as of September 2025: $54.38 Million USD
Based on the latest financial reports, NanoVibronix Inc (NAOV) holds total assets worth $54.38 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NanoVibronix Inc - Total Assets Trend (2011–2024)
This chart illustrates how NanoVibronix Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
NanoVibronix Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
NanoVibronix Inc's total assets of $54.38 Million consist of 91.8% current assets and 8.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.7% |
| Accounts Receivable | $268.00K | 7.4% |
| Inventory | $2.19 Million | 60.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how NanoVibronix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NanoVibronix Inc's current assets represent 91.8% of total assets in 2024, an increase from 86.9% in 2011.
- Cash Position: Cash and equivalents constituted 20.7% of total assets in 2024, down from 82.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 60.4% of total assets.
NanoVibronix Inc Competitors by Total Assets
Key competitors of NanoVibronix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
NanoVibronix Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - NanoVibronix Inc generates 0.70x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - NanoVibronix Inc is currently not profitable relative to its asset base.
NanoVibronix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.86 | 1.74 | 2.75 |
| Quick Ratio | 0.67 | 0.84 | 2.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.63 Million | $ 1.86 Million | $ 5.07K |
NanoVibronix Inc - Advanced Valuation Insights
This section examines the relationship between NanoVibronix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.04 |
| Latest Market Cap to Assets Ratio | 1.21 |
| Asset Growth Rate (YoY) | -45.6% |
| Total Assets | $3.63 Million |
| Market Capitalization | $4.37 Million USD |
Valuation Analysis
Above Book Valuation: The market values NanoVibronix Inc's assets above their book value (1.21 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: NanoVibronix Inc's assets decreased by 45.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NanoVibronix Inc (2011–2024)
The table below shows the annual total assets of NanoVibronix Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.63 Million | -45.62% |
| 2023-12-31 | $6.67 Million | +13.52% |
| 2022-12-31 | $5.88 Million | -31.81% |
| 2021-12-31 | $8.62 Million | +4.78% |
| 2020-12-31 | $8.23 Million | +304.17% |
| 2019-12-31 | $2.04 Million | +28.86% |
| 2018-12-31 | $1.58 Million | -67.52% |
| 2017-12-31 | $4.87 Million | +884.82% |
| 2016-12-31 | $494.00K | -75.09% |
| 2015-12-31 | $1.98 Million | +174.27% |
| 2014-12-31 | $723.00K | +4.63% |
| 2013-12-31 | $691.00K | +97.99% |
| 2012-12-31 | $349.00K | -67.83% |
| 2011-12-31 | $1.08 Million | -- |